Biogen Announces FDA ’s 3-Month Extension of Review Period for the New Drug Application for Tofersen

The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is April 25, 2023 CAMBRIDGE, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news